Funding for this research was provided by:
Takeda Pharmaceuticals U.S.A. (n/a)
Text and Data Mining valid from 2018-12-08
Received: 29 June 2018
Accepted: 22 November 2018
First Online: 8 December 2018
Compliance with ethical standards
: This research was conducted in accordance with the protocol procedures complied with the Declaration of Helsinki, the International Conference on Harmonisation (ICH) E6 GCP guidance, and all applicable local or regional regulatory requirements. The study was pre-registered with ExternalRef removed (identifier: NCT02079844), and hospital ethics approvals were given by NRES Committee South Central Berkshire (reference 12/SC/0443).
: SSS has received grant funding for clinical trials and/or honoraria for educational input from EnVivo Pharmaceuticals, Takeda, AbbVie and Janssen Pharmaceuticals. He is supported by a European Research Council Consolidator Award (Grant Number 311686) and the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. MAM has acted as a consultant for Cambridge Cognition, Lundbeck and FORUM pharmaceuticals in the past 5 years. He also has or has held research funding from Shire, Roche, Lundbeck and Takeda in the past 5 years. JG has acted as consultant for Quintiles CRO Ltd. YF, CD, SK, LV, AR and SCW have no disclosures or conflicts of interest to report. TU, GL and FO are employees of Takeda Development Center Americas, Inc., Chicago, U.S.A.MT is employed by Eli Lilly, Indianapolis, USA.